Methods for treating a Human Patient affected by multiple sclerosis or presents a clinically isolated Syndrome, Methods for treating a Human subject by providing neuroprotection to the Human subject.And Methods for treating a Human Patient affected by multiple sclerosis or presents a clinically isolated syndrome by increasing the time to progression of disease is confirmed, the increased time to Relapse or confirmed the reduction in brain atrophy Human patient,Which comprises administering to the Human Patient or subject orally Daily doses of approximately 1.2 mg laquinimod or a pharmaceutically acceptable Salt thereof.This also provides an oral pharmaceutical dosage Unit of approximately 1.2 mg laquinimod or a pharmaceutically acceptable Salt thereof and a pharmaceutically acceptable vehicle for use in the treatment of a Human Patient affected by multiple sclerosis or P Introduced a clinically isolated Syndrome,For use in the treatment of a Human subject by providing neuroprotection to the Human subject, or for use in the treatment of a Human Patient affected by multiple sclerosis or presents a clinically isolated Syndrome through the increased time to progression Disease was confirmed,The increased time to Relapse or confirmed the reduction of Brain atrophy in the Human patient.Métodos para tratar a un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado, métodos para tratar a un sujeto humano mediante la provisión de neuroprotección al sujeto humano, y métodos para tratar a un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado mediante el incremento del tiempo hasta progresión de enfermedad confirmada, el incremento del tiempo hasta recaída confirmada o la reducción de atrofia cerebral en el paciente humano, que comprende administrar oralmente al paciente humano o sujeto una dosis diaria de aproximadamente 1,2 mg de laquinimod o una sal del mismo farmacéuticamente aceptable.
